share_log

Genesis HealthCare System Builds on Its Investment in BIO-key Biometric Authentication Security as It Migrates to Epic Hyperdrive

Genesis HealthCare System Builds on Its Investment in BIO-key Biometric Authentication Security as It Migrates to Epic Hyperdrive

Genesis Healthcare System在遷移到Epic Hyperdrive時建立了對生物密鑰生物識別認證安全的投資
GlobeNewswire ·  2023/12/14 07:58

ZANESVILLE, Ohio and HOLMDEL, N.J., Dec. 14, 2023 (GLOBE NEWSWIRE) -- BIO-key International, Inc. (NASDAQ: BKYI), an innovative provider of workforce and customer Identity and Access Management (IAM) featuring passwordless, phoneless and token-less Identity-Bound Biometric (IBB) authentication solutions, announced that its longstanding customer Genesis HealthCare System, the largest healthcare provider in its six-county region of Ohio, will add BIO-key's PortalGuard IAM platform to support its existing BIO-key biometric authentication investment as it migrates to Epic Systems' Hyperdrive end-user application interface. Genesis HealthCare has a network of more than 300 physicians and 4,000 employees across 27 locations.

俄亥俄州贊斯維爾和新澤西州霍爾姆德爾,2023 年 12 月 14 日(GLOBE NEWSWIRE)— Biokey 國際公司(納斯達克股票代碼:BKYI)是一家創新的勞動力和客戶身份和訪問管理(IAM)提供無密碼、無電話和無令牌身份綁定生物識別(IBB)認證解決方案的提供商。該公司宣佈,其長期客戶Genesis Healthcare System是俄亥俄州六縣地區最大的醫療保健提供商,將在遷移時增加Bio-Key的PortalGuard IAM平台,以支持其現有的生物密鑰生物識別身份驗證投資 Epic Systems 的 Hyperdrive 最終用戶應用程序界面Genesis Healthcare在27個地點擁有由300多名醫生和4,000名員工組成的網絡。

PortalGuard's standards-based integration with Hyperdrive allows Genesis HealthCare System to continue enjoying the security and streamlined biometric authentication user experience that BIO-key provides without re-enrolling employees or adopting more cumbersome and expensive multi-factor authentication solutions.

PortalGuard與Hyperdrive的基於標準的集成使Genesis Healthcare System能夠繼續享受Bio-Key提供的安全和簡化的生物識別身份驗證用戶體驗,而無需重新註冊員工,也無需採用更繁瑣和更昂貴的多因素身份驗證解決方案。

Named by Computerworld as one of the 100 Best Places to Work in IT every year since 2017, Genesis Healthcare utilizes BIO-key biometric software and hardware to secure and streamline its users' login experience for Epic. By deploying PortalGuard IAM, it is able to maintain a consistent user experience and simplify the Hyperdrive migration. PortalGuard fully supports Hyperdrive's modern authentication approach through its SAML Identity Provider (IdP) capabilities. PortalGuard provides seventeen authentication factor options, including WEB-key fingerprint authentication, the same core BIO-key biometric authentication platform regularly used by thousands of Genesis HealthCare employees. Additionally, users can now use PortalGuard for biometric authentication in other hospital applications through its support for standard IdP integration options like SAML, OAUTH, and OpenID Connect.

自2017年以來,Genesis Healthcare被計算機世界評爲每年100個最佳IT工作場所之一,它利用Bio-Key生物識別軟件和硬件來保護和簡化用戶對Epic的登錄體驗。通過部署 PortalGuard IAM,它能夠保持一致的用戶體驗並簡化 Hyperdrive 遷移。PortalGuard 通過其 SAML 身份提供商 (IdP) 功能完全支持 Hyperdrive 的現代身份驗證方法。PortalGuard提供十七種身份驗證要素選項,包括網絡密鑰指紋身份驗證,這是成千上萬Genesis Healthcare員工經常使用的核心生物密鑰生物識別身份驗證平台。此外,通過支持 SAML、OAUTH 和 OpenID Connect 等標準 IdP 集成選項,用戶現在可以在其他醫院應用程序中使用 PortalGuard 進行生物識別身份驗證。

"Epic is a mission-critical application for many of BIO-key's hospital customers, and implementing PortalGuard SAML SSO allows Genesis to maintain streamlined workflows and ensure secure access to patient information with IBB," said Mark Cochran, President of BIO-key – PortalGuard. "Healthcare organizations face the challenge of providing convenient and reliable access to necessary systems while ensuring data privacy and regulatory compliance. BIO-key's Identity-Bound Biometrics allows customers to cost-effectively leverage a phoneless, tokenless, and cardless authentication experience that users prefer because it strikes the proper balance between security and convenience."

Bio-Key——PortalGuard總裁馬克·科克倫說:“對於Bio-Key的許多醫院客戶來說,Epic是一款任務關鍵型應用程序,實施PortalGuard SAML SSO使Genesis能夠保持簡化的工作流程,並確保使用IBB安全訪問患者信息。“醫療保健組織面臨的挑戰是提供對必要系統的便捷可靠訪問,同時確保數據隱私和監管合規性。Bio-Key的身份綁定生物識別技術使客戶能夠經濟高效地利用用戶首選的無電話、無令牌和無卡身份驗證體驗,因爲它在安全性和便利性之間取得了適當的平衡。”

About BIO-key International, Inc. ()
BIO-key is revolutionizing authentication and cybersecurity with biometric-centric, multi-factor identity and access management (IAM) software securing access for over thirty-five million users. BIO-key allows customers to choose the right authentication factors for diverse use cases, including phoneless, tokenless, and passwordless biometric options. Its hosted or on-premise PortalGuard IAM solution provides cost-effective, easy-to-deploy, convenient, and secure access to computers, information, applications, and high-value transactions.

關於 Bio-Key 國際有限公司 ()
Bio-Key 利用以生物識別爲中心的多因素身份和訪問管理 (IAM) 軟件,爲超過三千五百萬用戶提供訪問保護,從而徹底改變身份驗證和網絡安全。Bio-Key 允許客戶爲不同的用例選擇正確的身份驗證因素,包括無電話、無令牌和無密碼的生物識別選項。其託管或內部部署 PortalGuard IAM 解決方案提供經濟實惠、易於部署、便捷和安全的計算機、信息、應用程序和高價值交易的訪問。

BIO-key Safe Harbor Statement
All statements contained in this press release other than statements of historical facts are "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 (the "Act"). The words "estimate," "project," "intends," "expects," "anticipates," "believes" and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are made based on management's beliefs, as well as assumptions made by, and information currently available to, management pursuant to the "safe-harbor" provisions of the Act. These statements are not guarantees of future performance or events and are subject to risks and uncertainties that may cause actual results to differ materially from those included within or implied by such forward-looking statements. These risks and uncertainties include, without limitation, our history of losses and limited revenue; our ability to raise additional capital to satisfy debt repayment obligations and working capital needs; our ability to continue as a going concern; our ability to protect our intellectual property; changes in business conditions; changes in our sales strategy and product development plans; changes in the marketplace; continued services of our executive management team; security breaches; competition in the biometric technology industry; market acceptance of biometric products generally and our products under development; our ability to convert sales opportunities to customer contracts; our ability to expand into Asia, Africa and other foreign markets; our ability to integrate the operations and personnel of Swivel Secure into our business; fluctuations in foreign currency exchange rates; delays in the development of products and statements of assumption underlying any of the foregoing as well as other factors set forth under the caption "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2022 and other filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date made. Except as required by law, we undertake no obligation to disclose any revision to these forward-looking statements whether as a result of new information, future events, or otherwise.

Bio-key 安全港聲明
根據1995年《私人證券訴訟改革法》(“該法”)的定義,本新聞稿中包含的所有陳述均爲 “前瞻性陳述”,但歷史事實陳述除外。“估計”、“項目”、“打算”、“期望”、“預期”、“相信” 等詞語旨在識別前瞻性陳述。此類前瞻性陳述是基於管理層的信念,以及管理層根據該法的 “安全港” 條款做出的假設和管理層目前可以獲得的信息。這些陳述不能保證未來的業績或事件,並且存在風險和不確定性,這些風險和不確定性可能導致實際結果與此類前瞻性陳述中包含或暗示的結果存在重大差異。這些風險和不確定性包括但不限於我們的虧損歷史和收入有限;我們籌集額外資金以滿足債務償還義務和營運資金需求的能力;我們繼續作爲持續經營企業的能力;我們保護知識產權的能力;業務狀況的變化;我們的銷售策略和產品開發計劃的變化;市場的變化;我們執行管理團隊的持續服務;安全漏洞;生物識別技術行業的競爭;市場接受度一般的生物識別產品和我們正在開發的產品;我們將銷售機會轉化爲客戶合同的能力;我們向亞洲、非洲和其他國外市場擴張的能力;我們將 Swivel Secure 的運營和人員整合到我們的業務中的能力;外幣匯率的波動;產品開發的延遲和上述任何內容所依據的假設陳述,以及我們 10-K 表年度報告中標題爲 “風險因素” 的其他因素截至十二月三十一日止年度2022 年以及向美國證券交易委員會提交的其他文件。提醒讀者不要過分依賴這些前瞻性陳述,這些陳述僅代表截至發表之日。除非法律要求,否則我們沒有義務披露對這些前瞻性陳述的任何修訂,無論是由於新信息、未來事件還是其他原因。

Engage with BIO-key

使用 Bio-Key 互

Facebook – Corporate:
LinkedIn – Corporate:
Twitter – Corporate: @BIOkeyIntl
Twitter – Investors: @BIO_keyIR
StockTwits: BIO_keyIR
Facebook — 企業:
領英 — 企業:
推特 — 企業: @BIOkeyIntl
推特 — 投資者: @BIO_keyIR
StockTwits: bio_keyir

Investor Contacts

投資者聯繫方式

William Jones, David Collins
Catalyst IR
BKYI@catalyst-ir.com or 212-924-9800

威廉·瓊斯,大衛柯林斯
催化劑 IR
BKYI@catalyst-ir.com 或 212-924-9800


声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論